TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from PharmaTher Holdings Ltd ( (TSE:PHRM) ).
PharmaTher Holdings Ltd. has entered into an exclusive agreement with Oakwood Laboratories to evaluate and potentially license a patented long-acting injectable ketamine program. This initiative is part of PharmaTher’s strategy to enhance its ketamine franchise by offering a differentiated product that could redefine treatment standards for neuropsychiatric disorders. The program aims to provide more convenient dosing, improve patient adherence, and expand access to ketamine-based therapies, potentially offering significant commercial and strategic advantages.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders. The company aims to build a comprehensive ketamine franchise targeting treatment-resistant depression and major depressive disorders, leveraging innovative delivery technology and streamlined regulatory pathways.
YTD Price Performance: -34.78%
Average Trading Volume: 280,460
Technical Sentiment Signal: Sell
Current Market Cap: C$13.65M
For an in-depth examination of PHRM stock, go to TipRanks’ Overview page.